Prevent preclinical efficacy and intermediate biomarker endpoints task order: use of carnosic acid and VIVOX40 for breast cancer prevention
Ended Awarded Last action
- Contract number
- 75N91020F00001
- Awardee
-
University Of Illinois UEI W8XEAJDKMXH3 Part of University Of Illinois
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,683,323
Award facts
- Opportunity
- Contract value 100% obligated
- $1,683,322.63 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Chicago, IL 60612, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$131 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $611,872 | |
| Original award | $1,071,582 |
Show all 11
About this award
The National Cancer Institute issued a delivery order to the University of Illinois on July 1, 2020, with a ceiling value of $1,683,322.63 for preclinical efficacy and biomarker endpoint studies using carnosic acid and VIVOX40 for breast cancer prevention, under the PREVENT Preclinical Drug Development Program.
PREVENT is the parent Indefinite Delivery Contract supporting the National Cancer Institute's preclinical drug development research initiatives. The delivery order is firm fixed price. Place of performance is Chicago, IL. Ultimate completion date is December 31, 2025.
Quick answers
Who was awarded contract 75N91020F00001?
75N91020F00001 was awarded to University Of Illinois by National Cancer Institute (National Institutes of Health) on July 1, 2020.
How much is contract 75N91020F00001 worth?
The government has obligated $1,683,323 on 75N91020F00001.
Is contract 75N91020F00001 an order under another contract?
Yes. 75N91020F00001 is a delivery order under 75N91019D00016, an indefinite delivery contract, on PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91020F00001 competed?
The extent of competition for 75N91020F00001 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award